Administration of stable isotope-labelled leucine- (DrugBank: Leucine)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02263235 (ClinicalTrials.gov) | June 2013 | 18/9/2014 | In Vivo Alzheimer Proteomics | Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease | Probable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute Hydrocephaly | Biological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, saliva | University Hospital, Montpellier | Assistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy Agency | Recruiting | 55 Years | 85 Years | Both | 110 | N/A | France |